{"id":"iloprost-injection-for-intravenous-use","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Jaw pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iloprost mimics the action of prostacyclin (PGI2), a naturally occurring eicosanoid that regulates vascular tone and platelet function. By activating prostacyclin receptors, it causes direct vasodilation of pulmonary and systemic vasculature and reduces platelet activation and aggregation. This mechanism makes it effective in conditions characterized by pulmonary hypertension and peripheral vascular dysfunction.","oneSentence":"Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, promoting vasodilation and inhibiting platelet aggregation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:17.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"},{"name":"Raynaud's phenomenon secondary to systemic sclerosis"}]},"trialDetails":[{"nctId":"NCT03867097","phase":"PHASE2","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)","status":"COMPLETED","sponsor":"Civi Biopharma, Inc.","startDate":"2019-03-07","conditions":"Raynaud Phenomenon Secondary to Systemic Sclerosis","enrollment":34},{"nctId":"NCT04040322","phase":"PHASE3","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)","status":"COMPLETED","sponsor":"Civi Biopharma, Inc.","startDate":"2019-10-14","conditions":"Raynaud's Phenomenon Secondary to Systemic Sclerosis","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Iloprost Injection, for intravenous use","genericName":"Iloprost Injection, for intravenous use","companyName":"Civi Biopharma, Inc.","companyId":"civi-biopharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, promoting vasodilation and inhibiting platelet aggregation. Used for Pulmonary arterial hypertension, Raynaud's phenomenon secondary to systemic sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}